Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial

Broeckelmann, Paul J.; Buehnen, Ina; Meissner, Julia; Trautmann-Grill, Karolin; Herhaus, Peter; Halbsguth, Teresa V.; Schaub, Valdete; Kerkhoff, Andrea; Mathas, Stephan; Bormann, Matthias; Dickhut, Andreas; Kaul, Helen; Fuchs, Michael; Kobe, Carsten; Baues, Christian; Borchmann, Peter; Engert, Andreas; von Tresckow, Bastian

dc.contributor.author	Schaub, Valdete
dc.date.accessioned	2023-08-28T07:20:10Z
dc.date.available	2023-08-28T07:20:10Z
dc.date.issued	2023
dc.identifier.issn	0732-183X
dc.identifier.uri	http://hdl.handle.net/10900/145022
dc.language.iso	en	de_DE
dc.publisher	Lippincott Williams & Wilkins	de_DE
dc.relation.uri	http://dx.doi.org/10.1200/JCO.22.02355	de_DE
dc.subject.ddc	610	de_DE
dc.title	Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20230619000000_01085
utue.publikation.seiten	1193	de_DE
utue.personen.roh	Broeckelmann, Paul J.
utue.personen.roh	Buehnen, Ina
utue.personen.roh	Meissner, Julia
utue.personen.roh	Trautmann-Grill, Karolin
utue.personen.roh	Herhaus, Peter
utue.personen.roh	Halbsguth, Teresa V.
utue.personen.roh	Schaub, Valdete
utue.personen.roh	Kerkhoff, Andrea
utue.personen.roh	Mathas, Stephan
utue.personen.roh	Bormann, Matthias
utue.personen.roh	Dickhut, Andreas
utue.personen.roh	Kaul, Helen
utue.personen.roh	Fuchs, Michael
utue.personen.roh	Kobe, Carsten
utue.personen.roh	Baues, Christian
utue.personen.roh	Borchmann, Peter
utue.personen.roh	Engert, Andreas
utue.personen.roh	von Tresckow, Bastian
dcterms.isPartOf.ZSTitelID	Journal of Clinical Oncology	de_DE
dcterms.isPartOf.ZS-Issue	6	de_DE
dcterms.isPartOf.ZS-Volume	41	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE